Syndax Pharmaceuticals, Inc.
SNDX
$16.24
$0.402.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 68.82M | 43.72M | 23.68M | 16.00M | 3.50M |
| Total Other Revenue | 9.36M | -- | -- | -- | -- |
| Total Revenue | 78.18M | 43.72M | 23.68M | 16.00M | 3.50M |
| Cost of Revenue | 201.72M | 186.87M | 185.98M | 174.75M | 142.87M |
| Gross Profit | -123.54M | -143.14M | -162.30M | -158.75M | -139.37M |
| SG&A Expenses | 153.63M | 138.89M | 120.88M | 105.97M | 92.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 416.99M | 387.39M | 363.35M | 337.21M | 291.49M |
| Operating Income | -338.81M | -343.67M | -339.67M | -321.21M | -287.99M |
| Income Before Tax | -334.99M | -331.20M | -318.76M | -297.06M | -264.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -334.99 | -331.20 | -318.76 | -297.06 | -264.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -334.99M | -331.20M | -318.76M | -297.06M | -264.08M |
| EBIT | -338.81M | -343.67M | -339.67M | -321.21M | -287.99M |
| EBITDA | -338.80M | -343.66M | -339.66M | -321.20M | -287.98M |
| EPS Basic | -3.90 | -3.87 | -3.73 | -3.63 | -3.38 |
| Normalized Basic EPS | -2.44 | -2.42 | -2.33 | -2.27 | -2.11 |
| EPS Diluted | -3.90 | -3.87 | -3.73 | -3.64 | -3.39 |
| Normalized Diluted EPS | -2.44 | -2.42 | -2.33 | -2.27 | -2.11 |
| Average Basic Shares Outstanding | 343.73M | 342.67M | 341.71M | 328.44M | 312.86M |
| Average Diluted Shares Outstanding | 343.73M | 342.67M | 341.71M | 328.44M | 312.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |